Teriparatide Price Comparison

Live prices from 7 UK suppliers, from £49.00, compared side by side so you never overpay.

We compare prices & may earn a commission. We do not sell or supply any products. Full disclosure.

We may earn a commission from the suppliers listed here. Read our full disclosure.

Best Price £54.50
Average £91.50
Highest £110.00
You Could Save 50%
3 results
Best Price
Save 50%
NASS Peptides logo
NASS Peptides 50 /100 Confidence

Teriparatide 30mg

In Stock 30mg Lab Tested
£54.50
FREE delivery
Unavailable
Aura Peptides logo

Teriparatide 30mg

£109.99
50 /100 Confidence In Stock 30mg
FREE delivery
Nova Peptides logo

Teriparatide 30mg

£110.00
50 /100 Confidence In Stock 30mg Lab Tested
+ £5.00 delivery

Compare another peptide

PeptideSupermarket® compares prices but doesn't sell products.

All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.

We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.

By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.

Teriparatide Profile

Extensively Studied FDA Approved

PTH(1-34) | Bone-Building Anabolic Peptide

Overview

Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis drugs that slow bone loss, teriparatide actively stimulates new bone formation. The key to its mechanism is intermittent exposure: while continuous PTH causes bone resorption, daily injections stimulate osteoblasts more than osteoclasts, resulting in net bone formation. Clinical trials show 8% spine bone density increases and 65% reduction in vertebral fractures.

Mechanism of Action

Teriparatide binds to PTH type 1 receptors (G-protein coupled receptors) on osteoblasts, osteocytes, and renal tubular cells. This activates PKA and PKC signaling pathways that promote osteoblast activity. The intermittent daily dosing creates an 'anabolic window' where bone formation exceeds resorption. Teriparatide upregulates IGF-1 and FGF2 expression, stimulates bone formation on trabecular and cortical surfaces, and increases bone mineral density through preferential osteoblast stimulation.

Key Benefits

  • FDA-approved for osteoporosis treatment
  • Actively builds new bone (anabolic)
  • Increases spine bone density by 5-9%
  • Reduces vertebral fracture risk by 65%
  • Reduces nonvertebral fractures by 35%
  • Works differently than antiresorptive drugs
  • Benefits seen within 3 months
  • Creates 'anabolic window' for bone growth

Quick Stats

Typical Dose
20mcg daily (FDA-approved dose)
Frequency
Once daily at same time each day
Cycle Duration
Maximum 2 years lifetime treatment
Storage
Pen: 2-8°C refrigerated, do not freeze. Discard after 28 days

Molecular Information

Molecular Weight
4,118 Da
Length
34 amino acids
Type
Recombinant PTH fragment
Half-Life
~1 hour (subcutaneous); ~5 minutes (intravenous)

Amino Acid Sequence

N-terminal 1-34 of parathyroid hormone

Research Indications

The following information is derived from published scientific literature and is provided for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. These peptides are not approved for human use and are sold exclusively for in-vitro laboratory research.

Postmenopausal Osteoporosis

Most Effective

FDA-approved for women with osteoporosis at high risk of fracture.

Male Osteoporosis

Most Effective

FDA-approved for men with primary or hypogonadal osteoporosis at high risk.

Glucocorticoid-Induced Osteoporosis

Effective

FDA-approved for men and women with osteoporosis from sustained corticosteroid use.

Fracture Healing

Moderate

Research interest in accelerating fracture healing and bone repair.

Dental Bone Regeneration

Moderate

Investigated for jawbone regeneration in dental applications.

Dosing Protocols

injectable

Teriparatide is administered as a once-daily subcutaneous injection, typically in the thigh or abdomen. It comes in pre-filled pen devices (Forteo) containing a 28-day supply. Treatment is typically limited to 2 years due to theoretical bone cancer risk from long-term use (seen only in rats at high doses).

Goal Dose Frequency Route
Osteoporosis treatment 20 mcg Once daily SubQ (thigh or abdomen)

Key Tips

  • Convenient pre-filled pen device
  • Simple once-daily dosing
  • Well-established protocol
Materials Needed
Pre-filled pen device (Forteo) Pen needles Alcohol swabs
Steps
  1. 1 Store pen refrigerated (do not freeze)
  2. 2 Allow to reach room temperature before injection
  3. 3 Attach new needle for each injection
  4. 4 Inject subcutaneously in thigh or abdomen
  5. 5 Discard pen after 28 days even if medication remains

Peptide Interactions

Bisphosphonates

Sequential

Antiresorptive agents often needed after teriparatide to maintain bone gains. Can be used sequentially.

Calcium/Vitamin D

Synergistic

Adequate calcium and vitamin D intake recommended during teriparatide therapy.

BPC-157

Compatible

Different mechanisms; no known interactions.

TB-500

Compatible

Different mechanisms; no known interactions.

What to Expect

Month 1-3

Bone formation begins; spine BMD increases

Month 3-6

Continued bone density improvements

Month 6-12

5-9% spine BMD increase; fracture risk reduction

Year 1-2

Maximum benefits achieved; transition to maintenance

Side Effects & Safety

Common Side Effects

  • Injection site reactions
  • Nausea
  • Headache
  • Leg cramps
  • Dizziness
  • Joint pain

Monitoring

  • Serum calcium levels
  • Bone mineral density testing
  • Treatment limited to 2 years maximum
  • Follow with antiresorptive therapy to maintain gains

Stop Signs

  • Signs of hypercalcemia (confusion, fatigue, nausea)
  • Persistent bone pain
  • Allergic reactions

Contraindications

  • Paget's disease of bone
  • Prior skeletal radiation therapy
  • History of skeletal malignancies
  • Metabolic bone diseases other than osteoporosis
  • Pre-existing hypercalcemia
  • Pregnancy

Quality Checklist

Good Signs

  • Clear, colorless solution
  • Pharmaceutical grade (Forteo)
  • Proper cold chain maintained
  • Intact pen device

Warning Signs

  • Research-grade products lack FDA oversight
  • Temperature excursions may affect potency

Bad Signs

  • Cloudy or discolored solution
  • Particulates visible
  • Exposed to freezing or high temperatures

Research & References

Key References

  1. 2024

    Teriparatide

    StatPearls (NCBI Bookshelf)

    Intermittent PTH exposure induces bone formation more than resorption; FDA-approved for osteoporosis.

  2. 2002

    The effect of teriparatide therapy on bone density in men with osteoporosis

    PubMed

    Spine BMD increased 5.9% (20mcg) and 9.0% (40mcg); femoral neck increased 1.5-2.9%.

  3. 2006

    Teriparatide: 2.5 Years of Experience

    Journal of Bone and Mineral Research

    Reduced vertebral fractures by 65% and nonvertebral fractures by 35% after 20 months.

  4. 2006

    Parathyroid Hormone (1-84) and Teriparatide in Postmenopausal Osteoporosis

    Women's Health

    Initial formation without resorption creates 'anabolic window' for rapid bone volume increase.

Search PubMed for Teriparatide

Get Peptide Price-drop Alerts

Be the first to know when prices drop on your favourite peptides

Select peptides you're interested in:

No spam. Unsubscribe anytime. We respect your privacy.